June 19, 2012
Dainippon Sumitomo Pharma (DSP) announced on June 16 that it has obtained approval for the atypical antipsychotic drug Latuda (lurasidone hydrochloride) in Canada for the indication of acute schizophrenia in adults. The company plans to launch the drug in a...read more